REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 219 filers reported holding REATA PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.91 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $353,699 | +12.1% | 3,469 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $315,401 | -9.6% | 3,469 | 0.0% | 0.00% | -20.0% |
| Q3 2021 | $349,000 | -28.9% | 3,469 | 0.0% | 0.01% | -28.6% |
| Q2 2021 | $491,000 | +27.2% | 3,469 | -10.3% | 0.01% | +16.7% |
| Q1 2021 | $386,000 | -19.2% | 3,869 | 0.0% | 0.01% | -25.0% |
| Q4 2020 | $478,000 | +26.8% | 3,869 | 0.0% | 0.01% | +14.3% |
| Q3 2020 | $377,000 | -37.6% | 3,869 | 0.0% | 0.01% | -41.7% |
| Q2 2020 | $604,000 | +8.2% | 3,869 | 0.0% | 0.01% | 0.0% |
| Q1 2020 | $558,000 | -29.5% | 3,869 | 0.0% | 0.01% | -20.0% |
| Q4 2019 | $791,000 | +154.3% | 3,869 | 0.0% | 0.02% | +150.0% |
| Q3 2019 | $311,000 | -4.9% | 3,869 | +11.5% | 0.01% | -14.3% |
| Q2 2019 | $327,000 | +10.5% | 3,469 | 0.0% | 0.01% | +16.7% |
| Q1 2019 | $296,000 | +4.6% | 3,469 | 0.0% | 0.01% | 0.0% |
| Q3 2018 | $283,000 | – | 3,469 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $94,902,000 | 15.92% |
| Opaleye Management Inc. | 407,002 | $13,333,000 | 4.14% |
| Ikarian Capital, LLC | 649,600 | $21,281,000 | 2.80% |
| AWH Capital, L.P. | 150,000 | $2,459,457 | 2.54% |
| Boxer Capital, LLC | 1,239,000 | $40,590,000 | 2.09% |
| EcoR1 Capital, LLC | 1,975,611 | $64,721,000 | 2.02% |
| Camber Capital Management LP | 1,500,000 | $49,140,000 | 1.78% |
| MPM BioImpact LLC | 180,000 | $5,897,000 | 1.58% |
| Sofinnova Investments, Inc. | 602,545 | $19,739,000 | 1.50% |
| KRS Capital Management, LLC | 28,141 | $921,000 | 1.00% |